(HealthDay News) — For patients with moderate/severe atopic dermatitis (AD), those colonized with Staphylococcus aureus have a reduced immune response to intradermal influenza vaccination, according to a study published online Feb. 13 in the Journal of Allergy and Clinical Immunology.

Donald Y.M. Leung, M.D., Ph.D., from National Jewish Health in Denver, and colleagues compared antibody responses to intradermal vaccination among patients with moderate/severe AD versus non-atopic participants in an open-label study conducted at five sites during the 2012 to 2013 influenza season. A total of 347 participants were included and followed for 28 days after vaccination.

The researchers found that seroprotection rates for influenza B, H1N1, and H3N2 did not differ between participants with AD and non-atopic participants receiving intradermal vaccination, or for participants with AD receiving intradermal and intramuscular vaccination. Compared to noncolonized participants with AD, those with S. aureus colonization experienced lower seroprotection and seroconversion rates and lower hemagglutination-inhibition titer geometric mean fold increase against influenza B and lower seroconversion rates against influenza H1N1 after intradermal, but not intramuscular, vaccination.

Related Articles

“Because most patients with AD are colonized with S. aureus, intramuscular influenza vaccination should be given preference in these patients,” the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)